CME Group (CME)
Coverage summary
Aardvark Labs Capital Research has covered CME Group (CME) since July 24, 2025. The company is in the Financial Services sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 25, 2026. That report moved the rating from Outperform to Hold. The rating has changed twice since coverage began.
Translations: 5 in Chinese.
Rating history
All CME reports
Recap: Q3 2026
The Volume Record Is Real, but the Discount Is Gone: Downgrading CME to Hold
Recap: Q2 2026
The Step-Up Holds Against Its Hardest Comp, and the Perpetuals Panic Looks Like a Gift
Recap: Q1 2026
A Record 36.2 Million-Contract Quarter Across All Six Asset Classes, and a Stock That Shrugged
Recap: Q4 2025
A Fourth Straight Record Year and the Highest Q4 Volume Ever, but the Stock Sits at an All-Time High Into a 2026 Cost Step-Up
Recap: Q3 2025
Volumes Give Back the Record, but a Firmer Rate Per Contract, Record Market Data and Cost Discipline Hold EPS Flat
Recap: Q2 2025
The First 30 Million-Contract Quarter Sets Records Across the Board, but a Flat Tape and a Full Multiple Argue for Patience